| [1] |
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
|
| [2] |
van Dam PA, Tomatis M, Marotti L, et al. The effect of EUSOMA certification on quality of breast cancer care[J]. Eur J Surg Onco, 2015, 41(10): 1423-1429.
|
| [3] |
Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review[J]. Eur J Surg Oncol, 2010, 36(12): 1149-1155.
|
| [4] |
Gazelle GS, Goldberg SN, Solbiati L, et al. Tumor ablation with radio-frequency energy[J]. Radiology, 2000, 217(3): 633-646.
|
| [5] |
Singletary SE. New approaches to surgery for breast cancer[J]. Endocr Relat Cancer, 2001, 8(4): 265-286.
|
| [6] |
Jeffrey SS, Birdwell RL, Ikeda DM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology[J]. Arch Surg, 1999, 134(10): 1064-1068.
|
| [7] |
Noguchi M. Radiofrequency ablation treatment for breast cancer to meet the next challenge: how to treat primary breast tumor without surgery[J]. Breast Cancer, 2003, 10(1): 1-3.
|
| [8] |
Nguyen T, Hattery E, Khatri VP. Radiofrequency ablation and breast cancer: a review[J]. Gland Surg, 2014, 3(2): 128-135.
|
| [9] |
Grotenhuis BA, Vrijland WW, Klem TM. Radiofrequency ablation for early-stage breast cancer: treatment outcomes and practical considerations[J]. Eur J Surg Oncol, 2013, 39(12): 1317-1324.
|
| [10] |
Earashi M, Noguchi M, Motoyoshi A, et al. Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision[J]. Breast Cancer, 2007, 14(1): 39-47.
|
| [11] |
Kreb DL, Bosscha K, Ernst MF, et al. Use of cytokeratin 8 immunohistochemistry for assessing cell death after radiofrequency ablation of breast cancers[J]. Biotech Histochem, 2011, 86(6): 404-412.
|
| [12] |
Motoyoshi A, Noguchi M, Earashi M, et al. Histopathological and immunohistochemical evaluations of breast cancer treated with radiofrequency ablation[J]. J Surg Oncol, 2009, 102(5): 385-391.
|
| [13] |
Burak BW, Agnese DM, Povoski SP, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision[J]. Cancer, 2003, 98(7): 1369-1376.
|
| [14] |
Bloom KJ, Dowlat K, Assad L. Pathologic changes after interstitial laser therapy of infiltrating breast carcinoma[J]. Am J Surg, 2001, 182(4): 384-388.
|
| [15] |
Ferrero M, Spyratos F, Doussalg VL, et al. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors[J]. Cytometry, 1990, 11(6): 716-724.
|
| [16] |
Manenti G, Bolacchi F, Perretta T, et al. Small breast cancers: in vivo percutaneous US-guided radiofrequency ablation with dedicated cool-tip radiofrequency system[J]. Radiology, 2009, 251(2): 339-346.
|
| [17] |
Yamamoto N, Fujimoto H, Nakamura R, et al. Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer: evaluation with MRI and vacuum-assisted core needle biopsy and safety management[J]. Breast Cancer, 2011, 18(1): 3-9.
|
| [18] |
Vilar VS, Goldman SM, Ricci MD, et al. Analysis by MRI of residual tumor after radiofrequency ablation for early stage breast cancer[J]. AJR Am J Roentgenol, 2012, 198(3): 285-291.
|
| [19] |
Yoshinaga Y, Enomoto Y, Fujimitsu R, et al. Image and pathological changes after radiofrequency ablation of invasive breast cancer: a pilot study of nonsurgical therapy of early breast cancer[J]. World J Surg, 2013, 37(2): 356-363.
|
| [20] |
Boetes C, Mus RD, Holland R, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent[J]. Radiology, 1995, 197(3): 743-747.
|
| [21] |
Postma EL, van HR, Daniel BL, et al. MRI-guided ablation of breast cancer: where do we stand today?[J]. J Magn Reson Imaging, 2011, 34(2): 254-261.
|
| [22] |
Kim AY, Lee MW, Rhim H, et al. Pretreatment evaluation with contrast-enhanced ultrasonography for percutaneous radiofrequency ablation of hepatocellular carcinomas with poor conspicuity on conventional ultrasonography[J]. Korean J Radiol, 2013, 14(5): 754-763.
|
| [23] |
Wu J, Yang W, Yin S, et al. Role of contrast-enhanced ultrasonography in percutaneous radiofrequency ablation of liver metastases and efficacy evaluation[J]. Chin J Cancer Res, 2013, 25(2): 143-154.
|
| [24] |
Mauri G, Porazzi E, Cova L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment[J]. Insights Imaging, 2014, 5(2): 209-216.
|
| [25] |
Mauri G, Cova L, De BS, et al. Real-time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases[J]. Cardiovasc Intervent Radiol, 2015, 38(1): 143-151.
|
| [26] |
Schässburger KU, Löfgren L, Lagerstedt U, et al. Minimally-invasive treatment of early stage breast cancer: a feasibility study using radiofrequency ablation under local anesthesia[J]. Breast, 2014, 23(2): 152-158.
|